Cost and treatment for patients with lung cancer

Background

Treatment with EGFR-TKI (tyrosine kinase inhibitors) of patients with a specific variant of non-small cell lung cancer was approved in Norway 2009. We now want to know more about the costs and resources associated with this treatment.  

This project aims to describe treatment patterns of patients with locally advanced and metastatic non-small cell lung cancer, as well as investigate the use of health services and health economic costs.

The project has since been expanded to include patients diagnosed with localized lung cancer.

Data basis 

The project is based on data from Norwegian health registries. All patients registered in the Cancer Registry of Norway with the diagnosis locally advanced or metastatic non-small cell lung cancer in Norway from 2010 to 2017 will be included.   

Information about these patients will also be collected from the Norwegian Prescription Database, the Norwegian Patient Registry and the Cause of Death Registry. From these registries, we obtain data on issues such as diagnosis, treatment and drug consumption. Data are collected for both patients who have received treatment with EGFR-TKI and patients who have not been treated with EGFR-TKI. 

By linking these data, we will be able to investigate the use of health services and health economic costs associated with treatment with EGFR-TKI.

About the project

Project participants: Espen Enerly, Tom Børge Johannesen, Tor Åge Myklebust

Partners:
Klaus K Andersen, Mattias Ekman, Simona Conte, Jørgen Aarøe, AstraZeneca AB
Åslaug Helland, Oslo University Hospital HF

Funding: AstraZeneca AB

Duration: 2017 - ongoing

Scientific project name: Resource use patterns and healthcare costs in Patients with EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC in a Real World Setting - a nationwide cohort study 

Privacy: The Cancer Registry attaches great importance to information security for participants in our research projects. All information about participants is processed by persons with a duty of confidentiality. Read more about privacy

Licence Data Protection Authority: 17/01062-2/CDG

REC: The project has been approved by the Regional Committees for Medical and Health Research Ethics (ref. 2017/376).